The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Abstract
Arsenic on the Fingers: Arsenic, an ancient drug used in traditional Chinese medicine, has attracted wide interest because it has therapeutic activity in patients with acute promyelocytic leukemia (APL). The drug acts by promoting degradation of an oncogenic protein, PML-RARα, a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor α, which is found specifically in APL cells and helps drive their growth. Zhang et al. (p. 240 ; see the Perspective by Kogan ) now explain how arsenic initiates the molecular events leading to PML-RARα degradation. Arsenic was found to bind directly to cysteine residues within zinc finger domains of PML. Arsenic binding then induced oligomerization of PML, which in turn enhanced its association with an enzyme that helps catalyze SUMOylation, a posttranslational modification that can target proteins for degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One of the mechanisms by which ATO treats APL is its ability to bind directly to the cysteine in the zinc finger structure of the fusion protein, mediating the ubiquitinated degradation of PML-RARα.427”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [427]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Self-citationde Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355
Self-citationAcute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
Self-citationMelnick, A., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,028
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation
Tatham, M. H., Geoffroy, M.-C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E. G., Palvimo, J. J., & Hay, R. T. (2008) · Nature Cell Biology · doi:10.1038/ncb1716 · Cited by 847
Chen, G., Shi, X., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z., Ni, J.-H., Shi, G., Jia, P.-M., et al. (1997) · PubMed · Cited by 781
Self-citationArsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway
Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Zhou, J., Zhu, J., Raught, B., & de Thé, H. (2008) · Nature Cell Biology · doi:10.1038/ncb1717 · Cited by 734
Self-citationPML targeting eradicates quiescent leukaemia-initiating cells
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07016 · Cited by 538
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
Lu, J., Chew, E.-H., & Holmgren, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701549104 · Cited by 526
Cited by
Emerging Two-Dimensional Nanomaterials for Electrocatalysis
Jin, H., Guo, C., Liu, X., Liu, J., Vasileff, A., Jiao, Y., Zheng, Y., & Qiao, S.-Z. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00689 · Cited by 2,029
The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine
Tu, Y. (2011) · Nature Medicine · doi:10.1038/nm.2471 · Cited by 1,392
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Shen, S., Li, X.-F., Cullen, W. R., Weinfeld, M., & Le, X. C. (2013) · Chemical Reviews · doi:10.1021/cr300015c · Cited by 818
Hatakeyama, S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3139 · Cited by 802
Natural Products in Cancer Therapy: Past, Present and Future
Huang, M., Lu, J.-J., & Ding, J. (2021) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00293-7 · Cited by 648
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Chen, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2943 · Cited by 488
Self-citationHeavy Metals and Metalloids As a Cause for Protein Misfolding and Aggregation
Tamás, M., Sharma, S., Ibstedt, S., Jacobson, T., & Christen, P. (2014) · Biomolecules · doi:10.3390/biom4010252 · Cited by 468
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Chang, H.-M., & Yeh, E. T. H. (2020) · Physiological Reviews · doi:10.1152/physrev.00025.2019 · Cited by 355
Beauchamp, E. M., Ringer, L., Bulut, G., Sajwan, K. P., Hall, M. D., Lee, Y.-C., Peaceman, D., Özdemirli, M., Rodriguez, O., Macdonald, T. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42874 · Cited by 351
Kim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., Kim, J., Chen, B., King, E. M., Borodovsky, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.017 · Cited by 346
PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3
Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., Peres, L., Berthier, C., Soilihi, H., Raught, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.003 · Cited by 335
Self-citationWhat has traditional Chinese medicine delivered for modern medicine?
Wang, J., Wong, Y.-K., & Liao, F. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.3 · Cited by 328
Metabolism of arsenic and its toxicological relevance
Watanabe, T., & Hirano, S. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0904-5 · Cited by 324
Kim, J., Lee, J. J., Kim, J., Gardner, D., & Beachy, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006822107 · Cited by 304
Metabolism, toxicity and anticancer activities of arsenic compounds
Khairul, I., Wang, Q. Q., Jiang, Y. H., Wang, C., & Naranmandura, H. (2017) · Oncotarget · doi:10.18632/oncotarget.14733 · Cited by 300
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
de Thé, H., Pandolfi, P. P., & Chen, Z. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.002 · Cited by 297
Self-citationMetalloimmunology: The metal ion-controlled immunity
(2020) · Advances in Immunology · doi:10.1016/bs.ai.2019.11.007 · Cited by 292
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
Eifler, K., & Vertegaal, A. C. O. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.006 · Cited by 290
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
Gustafson, W. C., Meyerowitz, J. G., Nekritz, E. A., Chen, J., Benes, C., Charron, E., Simonds, E. F., Seeger, R., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 278
Targeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Regulation of transcription factor activity by interconnected post-translational modifications
Filtz, T. M., Vogel, W. K., & Leid, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.005 · Cited by 242
Kozono, S., Lin, Y.-M., Seo, H.-S., Pinch, B., Lian, X., Qiu, C., Herbert, M. K., Chen, C.-H., Tan, L., Gao, Z. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05402-2 · Cited by 168
Ben-Hail, D., Begas-Shvartz, R., Shalev, M., Shteinfer-Kuzmine, A., Gruzman, A., Reina, S., De Pinto, V., & Shoshan-Barmatz, V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744284 · Cited by 158
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability
Tsai, J. M., Aguirre, J. D., Li, Y.-D., Brown, J., Focht, V., Kater, L., Kempf, G., Sandoval, B., Schmitt, S., Rutter, J. C., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.028 · Cited by 68
Bercier, P., Wang, Q. Q., Zang, N., Zhang, J., Yang, C., Maimaitiyiming, Y., Abou-Ghali, M., Berthier, C., Wu, C., Niwa-Kawakita, M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0453 · Cited by 45
Self-citationp53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Zhang, X.-W., Yan, X.-J., Zhou, Z.-R., Yang, F.-F., Wu, Z.-Y., Sun, H.-B., Liang, W.-X., Song, A.-X., Lallemand-Breitenbach, V., Jeanne, M., Zhang, Q.-Y., Yang, H.-Y., Huang, Q.-H., Zhou, G.-B., Tong, J.-H., Zhang, Y., Wu, J.-H., Hu, H.-Y., de Thé, H., Chen, S.-J., & Chen, Z.
- Venue
- Science
- Published
- 2010-04-09
- Volume
- 328
- Issue
- 5975
- Pages
- 240-243
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2170325085
- Cited by
- 785
- References
- 27
- FWCI
- 24.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.